Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 2
2006 2
2015 1
2018 1
2019 1
2021 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Elastin imaging enables noninvasive staging and treatment monitoring of kidney fibrosis.
Sun Q, Baues M, Klinkhammer BM, Ehling J, Djudjaj S, Drude NI, Daniel C, Amann K, Kramann R, Kim H, Saez-Rodriguez J, Weiskirchen R, Onthank DC, Botnar RM, Kiessling F, Floege J, Lammers T, Boor P. Sun Q, et al. Sci Transl Med. 2019 Apr 3;11(486):eaat4865. doi: 10.1126/scitranslmed.aat4865. Sci Transl Med. 2019. PMID: 30944168 Free PMC article.
Fibrosis is the common endpoint and currently the best predictor of progression of chronic kidney diseases (CKDs). ...Elastin imaging allowed for repetitive and reproducible assessment of renal fibrosis, and it enabled longitudinal monitoring of therapeutic i …
Fibrosis is the common endpoint and currently the best predictor of progression of chronic kidney diseases (CKDs). ...Elastin imaging …
Current challenges in the treatment of cardiac fibrosis: Recent insights into the sex-specific differences of glucose-lowering therapies on the diabetic heart: IUPHAR Review 33.
Sharma A, De Blasio M, Ritchie R. Sharma A, et al. Br J Pharmacol. 2023 Nov;180(22):2916-2933. doi: 10.1111/bph.15820. Epub 2022 Mar 10. Br J Pharmacol. 2023. PMID: 35174479 Free PMC article. Review.
Several structural features underlie the development of diabetic cardiomyopathy and eventual diabetes-induced heart failure. Pathological cardiac fibrosis (interstitial and perivascular), in addition to capillary rarefaction and myocardial apoptosis, a …
Several structural features underlie the development of diabetic cardiomyopathy and eventual diabetes-induced heart failure. Patholog …
Evaluation of subclinical target organ damage for risk assessment and treatment in the hypertensive patients: left ventricular hypertrophy.
Agabiti-Rosei E, Muiesan ML, Salvetti M. Agabiti-Rosei E, et al. J Am Soc Nephrol. 2006 Apr;17(4 Suppl 2):S104-8. doi: 10.1681/ASN.2005121336. J Am Soc Nephrol. 2006. PMID: 16565230 Review.
Left ventricular hypertrophy (LVH) becomes a preclinical disease and an independent risk factor for congestive heart failure, ischemic heart disease, arrhythmia, sudden death, and stroke. In addition to elevated BP, several mechanisms are involved, including body si …
Left ventricular hypertrophy (LVH) becomes a preclinical disease and an independent risk factor for congestive heart failure, ischemi …
Heart Failure With Preserved Ejection Fraction in Diabetes: Mechanisms and Management.
Meagher P, Adam M, Civitarese R, Bugyei-Twum A, Connelly KA. Meagher P, et al. Can J Cardiol. 2018 May;34(5):632-643. doi: 10.1016/j.cjca.2018.02.026. Epub 2018 Mar 2. Can J Cardiol. 2018. PMID: 29731023 Review.
Furthermore, heart failure with preserved ejection fraction (HFpEF) is emerging as a significant clinical problem for patients with DM. Current clinical data suggest that between 30% and 40% of patients with HFpEF suffer from DM. The typical structural phenotype of the HFp …
Furthermore, heart failure with preserved ejection fraction (HFpEF) is emerging as a significant clinical problem for patients with D …
Cardioreparation with lisinopril in the management of hypertension and heart failure.
Weber KT, Brilla CG, Janicki JS. Weber KT, et al. Cardiology. 1991;79 Suppl 1:62-73. doi: 10.1159/000174908. Cardiology. 1991. PMID: 1655265 Review.
In certain disease states, particularly arterial hypertension, components of the hypertrophic remodelling process, other than myocyte growth, distort myocardial structure and thereby adversely alter its mechanical behaviour. Such a pathologic structural remodelling includes a …
In certain disease states, particularly arterial hypertension, components of the hypertrophic remodelling process, other than myocyte growth …
From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease.
Gradman AH, Alfayoumi F. Gradman AH, et al. Prog Cardiovasc Dis. 2006 Mar-Apr;48(5):326-41. doi: 10.1016/j.pcad.2006.02.001. Prog Cardiovasc Dis. 2006. PMID: 16627048 Review.
LVH involves changes in myocardial tissue architecture consisting of perivascular and myocardial fibrosis and medial thickening of intramyocardial coronary arteries, in addition to myocyte hypertrophy. ...The latter is directly related to the degree of myocardial …
LVH involves changes in myocardial tissue architecture consisting of perivascular and myocardial fibrosis and medial thickenin …
Long-term treatment in arterial hypertension for protecting hypertrophic myocardium.
Vogt M, Motz W, Strauer BE. Vogt M, et al. Basic Res Cardiol. 1991;86 Suppl 3:223-33. doi: 10.1007/978-3-662-30769-4_22. Basic Res Cardiol. 1991. PMID: 1838250 Review.
The cardiac organ manifestation of arterial hypertension comprises the myocardium itself with left-ventricular hypertrophy, the interstitium with perivascular and interstitial fibrosis, and the coronary circulation with disease of large and small coronary art …
The cardiac organ manifestation of arterial hypertension comprises the myocardium itself with left-ventricular hypertrophy, the inter …
Anthracycline treatment and ventricular remodeling in left ventricular assist device patients.
Segura AM, Radovancevic R, Demirozu ZT, Frazier OH, Buja LM. Segura AM, et al. Tex Heart Inst J. 2015 Apr 1;42(2):124-30. doi: 10.14503/THIJ-14-4509. eCollection 2015 Apr. Tex Heart Inst J. 2015. PMID: 25873821 Free PMC article.
We evaluated those samples for hypertrophy, myocytolysis, and fibrosis. Histopathologic findings showed moderate-to-severe myocyte hypertrophy, moderate myocytolysis, and perivascular and interstitial fibrosis with areas of replacement fibrosis. ...The …
We evaluated those samples for hypertrophy, myocytolysis, and fibrosis. Histopathologic findings showed moderate-to-severe myocyte hy …
Comparative analysis on the anti-inflammatory/immune effect of mesenchymal stem cell therapy for the treatment of pulmonary arterial hypertension.
Oh S, Jang AY, Chae S, Choi S, Moon J, Kim M, Spiekerkoetter E, Zamanian RT, Yang PC, Hwang D, Byun K, Chung WJ. Oh S, et al. Sci Rep. 2021 Jan 21;11(1):2012. doi: 10.1038/s41598-021-81244-1. Sci Rep. 2021. PMID: 33479312 Free PMC article.
Despite the advancement of targeted therapy for pulmonary arterial hypertension (PAH), poor prognosis remains a reality. ...The UCB-MSCs treated group also exhibited the greatest improvement in terms of the largest decrease in the medial wall thickness, perivascular …
Despite the advancement of targeted therapy for pulmonary arterial hypertension (PAH), poor prognosis remains a reality. ...The UCB-M …